Evaluating the efficacy of seasonal influenza vaccine in pemphigus Patients

Evaluation of the efficacy of seasonal influenza vaccine in pemphigus Patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191022045185N1

Enrollment

Registered

2020-01-20

Start date

2019-10-21

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pemphigus disease. Pemphigus vulgaris

Interventions

Intervention 1: Intervention group: Pemfigus-controlled patients receiving minimal dose therapy receive one injection for seasonal influenza vaccine patients. Intervention 2: Control group: Pemphigus

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: pemphigus Patients Patients treated with minimal dose therapy (disease in control phase) A history of receiving a biological drug more than six months ago

Exclusion criteria

Exclusion criteria: The patient is in the active phase of the disease Be treated with high doses of the drug received a biological drug six months ago

Design outcomes

Primary

Measure	Time frame
Evaluation of the effectiveness of seasonal influenza vaccine in relapse rate of pemphigus in patients under control of pemphigus. Timepoint: before and every three month. Method of measurement: PDAI ,Dsg1/3.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contacthamidreza mahmoody

Tehran University of Medical Sciences

hr_mahmoody@yahoo.com+98 21 5569 6708

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026